NCT01058655View on ClinicalTrials.gov

RAD001 and AV-951 in Patients With Refractory, Metastatic Colorectal Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

February 28, 2010

Primary Completion Date

September 30, 2013

Study Completion Date

April 30, 2015

Conditions
Gastrointestinal Cancer
Interventions
DRUG

Everolimus

DRUG

Tivozanib

Trial Locations (3)

02114

Massachusetts General Hospital, Boston

02115

Beth Israel Deaconess Medical Center, Boston

Dana-Farber Cancer Institute, Boston

Sponsors
All Listed Sponsors
collaborator

Brigham and Women's Hospital

OTHER

collaborator

Massachusetts General Hospital

OTHER

collaborator

Beth Israel Deaconess Medical Center

OTHER

collaborator

Novartis

INDUSTRY

collaborator

AVEO Pharmaceuticals, Inc.

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER